Doxycycline Induces Expression of P Glycoprotein in MCF-7 Breast Carcinoma Cells by Katrina L. Mealey et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2002, p. 755–761 Vol. 46, No. 3
0066-4804/02/$04.000 DOI: 10.1128/AAC.46.3.755–761.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Doxycycline Induces Expression of P Glycoprotein in
MCF-7 Breast Carcinoma Cells
Katrina L. Mealey,1 Rola Barhoumi,2 Robert C. Burghardt,2 Stephen Safe,1
and Deborah T. Kochevar1*
Department of Veterinary Physiology and Pharmacology1 and Veterinary Anatomy and Public Health,2 Texas A&M
University College of Veterinary Medicine, College Station, Texas 77843-4466
Received 13 April 2001/Returned for modification 20 September 2001/Accepted 10 December 2001
P-glycoprotein (P-gp) overexpression by tumor cells imparts resistance to multiple antineoplastic chemo-
therapeutic agents (multiple drug resistance). Treatment of tumor cells with chemotherapeutic agents such as
anthracyclines, epipodophyllotoxins, and Vinca alkaloids results in induction of P-gp expression. This study
was performed to determine if clinically relevant antimicrobial drugs (i.e., drugs that are used to treat bacterial
infections in cancer patients) other than antineoplastic agents can induce expression of P-gp in MCF-7 breast
carcinoma cells. Expression of P-gp and MDR1 mRNA was determined in samples from MCF-7 cells that were
treated in culture with doxorubicin (positive control) and the antimicrobial drugs doxycycline, piperacillin, and
cefoperazone. The functional status of P-gp was assessed using laser cytometry to determine intracellular
doxorubicin concentrations. The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay
was used to determine if the cytotoxicity of experimental drugs was related to their ability to induce P-gp
expression. MCF-7 cells treated with doxycycline (MCF-7/doxy) were stimulated to overexpress P-gp, whereas
cells treated with piperacillin and cefoperazone did not overexpress P-gp. MCF-7/doxy cells were compared to
a positive-control subline, MCF-7/Adr, previously selected for doxorubicin resistance, and to MCF-7 cells
treated with doxorubicin (MCF-7/doxo). All three sublines overexpressed P-gp and MDR1 mRNA and accu-
mulated less intracellular doxorubicin than did control MCF-7 cells. P-gp expression was induced only by
experimental drugs that were cytotoxic (doxorubicin and doxycycline). Doxycycline, a drug that has been used
for treatment of bacterial infections in cancer patients, can induce functional P-gp expression in cancer cells,
resulting in multidrug resistance.
In 1970, Biedler and Riehm (3) described an in vitro model
of chemotherapeutic multidrug resistance (MDR) in which
cultured cells that were selected for growth in actinomycin D
developed resistance to a variety of structurally and function-
ally diverse cytotoxic compounds. Further studies showed that
the emergence of MDR was associated with increased levels of
a transmembrane glycoprotein (24), P glycoprotein (P-gp).
P-gp, the product of the MDR1 gene, is a 170-kDa protein that
functions as an energy-dependent drug efflux pump whose
substrates include naturally occurring, lipophilic agents with a
complex ring structure such as Vinca alkaloids, anthracyclines,
epipodophyllotoxins, and certain rhodamine dyes (18, 26, 37).
Exposure of tumor cells to any of these substrates can generate
overexpression of P-gp, resulting in the MDR phenotype.
Drug exposure is thought to cause overexpression of P-gp by
both selection of resistant cells and induction of P-gp expres-
sion at the level of the MDR1 promoter (14, 34). The MDR1
promoter contains a heat-shock consensus element (46) and a
putative xenobiotic response element that responds directly to
treatment with cytotoxic agents (25, 45), supporting the
premise that induction of P-gp expression occurs in the pres-
ence of chemotherapeutic agents. Additionally, there is a cor-
relation between specific point mutations in the MDR1
promoter and increased inducibility after treatment with che-
motherapeutic agents (45). Collectively, these studies provide
supportive evidence that induction of P-gp overexpression, as a
direct result of exposure to chemotherapeutic agents, does
occur in vitro. Such evidence is lacking in the clinical setting,
where it is unclear whether apparently increasing levels of P-gp
expression are a result of selection of a P-gp-expressing sub-
population of cells or induction of P-gp expression.
However, considerable data document the importance of
P-gp-mediated MDR in clinical cancer patients. Expression of
P-gp has been documented elsewhere for tumor specimens
derived from patients with a variety of histologic types of can-
cer (8, 20, 31, 38). Results from these clinical investigations
were similar to in vitro results described above: P-gp expres-
sion was increased in patients with a history of exposure to
chemotherapeutic drugs. Clinical studies of different malignant
tumors have shown the progressive development of P-gp over-
expression during chemotherapy, confirming the hypothesis
that exposure to antineoplastic agents results in selection (or
induction) of MDR clones of tumor cells (4, 41). Emergence of
these resistant clones often leads to relapse of disease and
therapeutic failure. For many tumor types, a relationship be-
tween P-gp expression and an adverse clinical course has been
observed previously (1, 6, 7). Although the role of P-gp in
human cancer is not entirely defined, the consensus view is that
P-gp overexpression is associated with clinical evidence of drug
resistance and treatment failure for a significant number of
cancer patients (22, 34).
As a result of these observations, chemotherapeutic treat-
ment protocols are manipulated so as to prevent the develop-
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ment of P-gp expression. Protocols are designed to circumvent
the proliferation of resistant tumor cells by judiciously com-
bining multiple drugs and delivering them at optimal doses and
intervals (34). Considerable effort is made to avoid drugs that
may have only sporadic activity against a specific tumor and yet
are likely to select for MDR. In contrast, little attention is
granted to the possibility that P-gp expression may be affected
by other drugs that are administered to cancer patients. Many
cancer patients are immunocompromised, as a direct conse-
quence of their disease or from treatment for their disease, and
are predisposed to bacterial infections. Such patients often
undergo antimicrobial therapy either prophylactically or for
active bacterial infections. Administration of an antimicrobial
drug that enhances the development of MDR could promote
therapeutic failure.
P-gp shares a high degree of homology with bacterial trans-
port proteins (9, 35) and displays characteristics of bacterial
multidrug efflux systems (36). Interestingly, one of the same
drugs that is used to generate overexpression of P-gp in mam-
malian cells, rhodamine, is capable of generating expression of
a homologous bacterial transport protein. Bacillus subtilis cells
selected for rhodamine 6G resistance display amplification of
the gene coding for a prokaryotic MDR transporter. This mul-
tidrug efflux system transports similar drugs (puromycin,
ethidium bromide, and rhodamine) and is sensitive to the same
inhibitors (verapamil and reserpine) as is the mammalian mul-
tidrug transporter P-gp (36). These observations led to the
hypothesis that exposure of cancer cells to antimicrobial drugs
would result in the emergence of a P-gp-expressing MDR
subline. To test this hypothesis, three agents were selected,
each representing a different antimicrobial drug class. Doxycy-
cline, a tetracycline antimicrobial agent, was selected because
of its structural similarity to doxorubicin (Fig. 1), and because
of its lipophilicity among the tetracyclines (13). Both doxycy-
cline and doxorubicin are elaborated by strains of the genus
Streptomyces (5, 42). Cefoperazone, a cephalosporin antimicro-
bial agent, was selected because of its ability to modulate P-gp
function, as it has been reported previously that some P-gp
modulators are actually substrates of P-gp (40). Piperacillin, a
semisynthetic penicillin, was selected because it contains a
piperazine group, a chemical moiety that plays an important
role in substrate binding to P-gp (21). The well-defined human
breast carcinoma cell line MCF-7 was incubated with increas-
ing concentrations of doxycycline, cefoperazone, piperacillin,
and the antineoplastic drug doxorubicin (positive control). Ex-
posure of MCF-7 cells to the antimicrobial agent doxycycline
FIG. 1. Chemical structures of doxorubicin and doxycycline.
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produces a P-gp-overexpressing cell line with properties that
are identical to those of well-characterized MDR cell lines
generated following incubation of cells with antineoplastic
agents. The fact that P-gp overexpression was generated in a
previously P-gp-negative cell clone provides supportive evi-
dence that induction of P-gp overexpression, rather than se-
lection of a resistant cell population, is responsible for gener-
ating MDR in cell culture systems.
MATERIALS AND METHODS
Drugs. Doxycycline and cefoperazone were generously provided by Pfizer
(New York, N.Y.), and piperacillin was provided by Lilly Laboratories (India-
napolis, Ind.). Doxorubicin and verapamil were obtained from Sigma Chemical
Company (St. Louis, Mo.).
Cells and culture conditions. MCF-7 and MCF-7/Adr (27) cell lines were the
generous gift of Kenneth Cowan of the National Cancer Institute (Bethesda,
Md.) and were maintained in RPMI 1640 medium supplemented with 10% fetal
bovine serum at 37°C in a humidified atmosphere containing 5% CO2–95% air.
MCF-7/Adr cells were periodically incubated in 3 M doxorubicin to ensure that
high levels of P-gp expression were maintained. Prior to experiments, MCF-7/
Adr cells were incubated without drug for 48 h. With an enzyme-linked immu-
nosorbent assay–PCR system (Boehringer Mannheim, Indianapolis, Ind.), cells
were found to be free of contamination by Mycoplasma species.
In order to ascertain whether development of P-gp expression resulted from
selection of a previously resistant clone of cells or from induction of P-gp
expression, experimental cells were obtained from a single cell clone. This was
accomplished by serially diluting MCF-7 cells to a concentration of 0.5 cells/250
l of medium and instilling 250 l per well in a 96-well plate. The plate was
examined microscopically to identify wells containing a single cell. One such cell
was expanded for utilization in these studies. No P-gp or MDR1 mRNA expres-
sion was detected in this clone as determined by immunoblotting or Northern
analysis, respectively (data not shown). The expanded clone of MCF-7 cells was
grown in 25-cm2 dishes and incubated without drug (negative control) or with
doxorubicin (as an internal control), doxycycline, cefoperazone, or piperacillin.
Initial drug concentrations were as follows: doxorubicin, 0.01 g/ml; doxycycline,
3 g/ml; cefoperazone, 20 g/ml; and piperacillin, 20 g/ml. These concentra-
tions represent plasma drug levels achievable by therapeutic dose regimens.
Fresh drug was added each time that the medium was changed (approximately
every 48 to 72 h). Drug concentrations were increased in a stepwise manner, with
subsequent concentrations being approximately 1.5- to 3-fold greater than pre-
vious concentrations. Aliquots of cell sublines were cryopreserved at each incre-
mental concentration. After 24 h of incubation at the higher drug concentration,
cells were inspected microscopically, and sublines that appeared unhealthy based
on visual inspection were subjected to trypan blue exclusion. If cell viability was
less than 50 to 60%, drug concentration was reduced to previous levels for
approximately 1 week. Drug concentration was then increased to a level approx-
imately 1.25- to 1.3-fold greater than the previous concentration. Final concen-
trations of drugs were as follows: doxorubicin, 2 g/ml (3 M); doxycycline, 100
g/ml (208 M); cefoperazone, 2 mg/ml (3 mM); and piperacillin, 8 mg/ml (14
mM). Solubility problems prevented further increases in cefoperazone and pip-
eracillin concentrations. The duration of drug exposure was approximately 12
weeks for doxorubicin and doxycycline and 16 weeks for cefoperazone and
piperacillin.
Northern analysis. Total cellular RNA was extracted from cell pellets by the
guanidinium thiocyanate method (11). The RNA concentration was determined
spectrophotometrically, and 10 g was loaded into each well of an agarose gel
and electrophoresed. RNA was transferred to a nylon membrane, cross-linked
using UV irradiation, and prehybridized (15 min at 65°C) in RapidHyb buffer
(Amersham, Cleveland, Ohio). A 32P-labeled cDNA probe (approximately 5 
106 cpm/ml of hybridization buffer) corresponding to nucleotides 1178 to 2561 of
the human MDR1 gene (Michael Gottesman, National Cancer Institute) was
allowed to hybridize for 2 h at 65°C. The membrane was then washed twice for
15 min in 0.1 SSC (0.015 M NaCl, 0.0015 M Na3 citrate)–0.1% sodium dodecyl
sulfate at 25°C, exposed to autoradiography film, and developed after approxi-
mately 24 h. Procedures for the glyceraldehyde-3-phosphate dehydrogenase
probe (cDNA probe for human glyceraldehyde-3-phosphate dehydrogenase
[ATCC 57091]; American Type Culture Collection, Manassas, Va.) were iden-
tical to those used for the MDR1 probe.
Immunoblotting. Cells were harvested by trypsinization, washed with Dulbec-
co’s phosphate-buffered saline solution (Sigma Chemical Company), and solu-
bilized in tumor solubilization buffer (50 mM Tris HCl [pH 6.8], 50 mM KCl, 5
mM EGTA, 5 mM MgCl2, 2% 3-[(3-cholamidopropyl)-dimethylammonio]-1-
propanesulfonate [CHAPS], 0.1 mM leupeptin, 0.2 mM phenylmethylsulfonyl
fluoride, and 10 mM dithiothreitol). Insoluble complexes were cleared by a
1,500-rpm, 5-min spin, and the soluble protein was collected for quantitation by
a modified Lowry technique (30). Samples containing 50 g of protein per well
were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and electroblotted onto an Immobilon-P membrane (Millipore, Bedford, Mass.).
Membranes were washed with BLOTTO buffer (50 mM Tris HCl, 2 mM CaCl2,
80 mM NaCl, 5% nonfat dry milk, 0.2% Nonidet P-40, 0.03% sodium azide) for
1 h at 25°C and then incubated (25°C for 16 h) with C219 anti-P-gp monoclonal
antibody (Signet, Dedham, Mass.). Actin was subsequently detected with a
monoclonal antiactin antibody (ICN Immunobiologicals, Costa Mesa, Calif.).
Membranes were washed in fresh BLOTTO buffer and incubated with the
appropriate alkaline phosphatase-labeled secondary antibody. Membranes were
washed with buffer A (50 mM Tris HCl, 2 mM CaCl2, 80 mM NaCl) and
developed by using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphos-
phate with an alkaline phosphatase-conjugated substrate kit (Bio-Rad Labora-
tories, Hercules, Calif.). The color reaction was terminated by washing the
reaction mixture in distilled water. Resulting bands were scanned with a Visage
110 camera-based densitometer (BioImage, Ann Arbor, Mich.) and analyzed
with whole-band software. Integrated intensity signals for P-gp were normalized
to those for actin in the analysis since actin levels were not expected to change
under the experimental conditions.
Laser cytometric analysis of doxorubicin accumulation-efflux. Functional
analysis of P-gp took advantage of the inherent fluorescence of doxorubicin,
which accumulates in sensitive cells but is actively exported from cells expressing
a functional P-gp. The reduced doxorubicin fluorescence in P-gp-expressing cells
is blocked by verapamil (16), causing accumulation of cytoplasmic fluorescence.
Cells were maintained in drug-free medium for 48 h prior to doxorubicin accu-
mulation studies and then harvested from 25-cm2 tissue culture flasks by
trypsinization. Cells were seeded in chambered borosilicate cover glass slides
(100,000 cells per well) (Nunc Inc., Naperville, Ill.) and incubated for 36 h (37°C,
humidified 5% CO2) to allow cells to adhere to chamber slides. Doxorubicin (5
M) or doxorubicin plus verapamil (10 M) were added to the chamber slides.
Chamber slides containing cells but no drug were used as negative controls. Cells
were incubated with drug for approximately 18 h, washed once with Dulbecco’s
phosphate-buffered saline, and examined immediately by laser cytometry (Me-
ridian Ultima Workstation; Meridian Instruments, Okemos, Mich.) to quantitate
intracellular fluorescence intensity. To relate fluorescence intensities of doxoru-
bicin obtained by laser cytometry from different treatments to intracellular doxo-
rubicin concentration, excitation and detection parameters were kept constant,
and a suspension calibration curve was generated with graded concentrations (0
to 2 mM) of doxorubicin in suspension. Correction for differences in optical
thickness between suspension analysis and intracellular doxorubicin concentra-
tion was accomplished according to previously described methods (2). The laser
cytometer was set at an excitation wavelength of 488 nm, and the emitted
fluorescence was detected with a barrier filter (band pass 530/30). Ten micro-
scopic fields, each containing aggregates of 10 to 15 cells, were analyzed for each
treatment. At least two experiments on different days were performed. For each
subline, comparisons between doxorubicin and doxorubicin plus verapamil flu-
orescence intensity data were performed with the Student t test. Between-treat-
ment group comparisons of sublines were performed with Duncan’s new multiple
range test of the General Linear Models analysis of variance procedure of
SAS-STAT (1985) with significance set at P  0.05.
Cytotoxicity (MTT) assay. MCF-7 and MCF-7/Adr cells were plated in 24-well
plates at 105 cells per well and allowed to adhere to the plate overnight. Cells
underwent a 24-h treatment with experimental drugs alone or in combination
with verapamil. Corresponding controls received either no drug treatment or
treatment with verapamil only. On the day of assay, treatment medium was
replaced with fresh medium containing 0.83 mg of MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide) per ml and incubated for 4 h. Medium
was then aspirated off, and 200 l of dimethyl sulfoxide was added to wells to
solubilize crystals. The optical density of each sample was read on a microplate
reader (model 7520; Cambridge Technology, Inc., Watertown, Mass.) at 570 nm
against a blank prepared from cell-free wells. Cell survival was expressed as a
fraction of that of untreated controls.
RESULTS
Northern hybridization and immunoblot analysis. Northern
blot analysis showed that P-gp mRNA levels could not be
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detected in RNA extracts from uninduced parental cells
(MCF-7), nor in extracts from cells incubated with either ce-
foperazone (MCF-7/cef) or piperacillin (MCF-7/pip) (Fig. 2).
In contrast, a 4.5-kb band was visible in lanes containing RNA
from MCF-7/Adr (positive-control) cells and from cells treated
with either doxorubicin (MCF-7/doxo) or doxycycline (MCF-
7/doxy), indicating increased MDR1 gene expression. Immu-
noblotting of cellular extracts with a monoclonal anti-human
P-gp antibody (C219) confirmed high levels of P-gp expression
(Fig. 3) in protein extracts from MCF-7/Adr, MCF-7/doxo, and
MCF-7/doxy cells, whereas immunoreactive P-gp was not de-
tected in extracts of MCF-7, MCF-7/pip, and MCF-7/cef cells.
Laser cytometric analysis of doxorubicin accumulation-ef-
flux. In order to examine the phenotype associated with P-gp
expression, intracellular doxorubicin accumulation was as-
sessed by means of laser cytometry. Intracellular doxorubicin
accumulation in MCF-7/Adr, MCF-7/doxo, and MCF-7/doxy
cells was significantly less than that in MCF-7, MCF-7/cef, and
MCF-7/pip cells (data not shown). Intracellular doxorubicin
accumulation was also assessed after incubating cells with both
doxorubicin and the P-gp-reversing agent verapamil, which
prevents P-gp-mediated drug efflux. Figure 4 shows computer-
generated images of the fluorescence intensity, representing
intracellular doxorubicin accumulation, of MCF-7/Adr and
MCF-7/doxy cells in the presence and absence of verapamil.
Intracellular concentrations of doxorubicin in MCF-7, MCF-
7/Adr, and MCF-7/doxy cells incubated with doxorubicin alone
and in combination with verapamil are summarized in Table 1.
Both MCF-7/Adr and MCF-7/doxy cells have significantly
lower intracellular doxorubicin concentrations than do MCF-7
cells when incubated with doxorubicin, indicating functional
expression of P-gp. Addition of verapamil completely reverses
the P-gp phenotype, resulting in comparable intracellular
doxorubicin concentrations in MCF-7, MCF-7/Adr, and MCF-
7/doxy cells. Interestingly, when MCF-7/doxy cells were incu-
bated with doxorubicin alone, they accumulated significantly
less doxorubicin than did the positive-control cell line, MCF-
7/Adr. These results indicate that P-gp function is independent
of the drug used to generate its expression.
MTT cytotoxicity assay. Cytotoxicity assays were performed
to determine whether the experimental drug’s ability to gen-
erate P-gp overexpression was related to its degree of cytotox-
icity. Such a relationship would lend support to the theory that
P-gp-overexpressing cell lines are generated by selection of a
small population of MDR cells. From a teleological perspec-
tive, the role of P-gp is to protect cells from potentially toxic
xenobiotics (43). Therefore, cells that express P-gp have the
FIG. 2. Expression of MDR1 mRNA in MCF-7 cell sublines. Total
cellular RNA (10 g) was electrophoresed, transferred, hybridized
with 32P-labeled MDR1 cDNA, and processed for autoradiography. A
glyceraldehyde-3-phosphate dehydrogenase (GA3PDH) probe was
utilized to normalize RNA load (lower panel). Final concentrations of
drugs were as follows: doxorubicin, 2 g/ml (3 M); doxycycline, 100
g/ml (208 M); cefoperazone, 2 mg/ml (3 mM); and piperacillin, 8
mg/ml (14 mM). Solubility problems prevented further increases in
cefoperazone and piperacillin concentrations. The duration of drug
exposure was approximately 12 weeks for doxorubicin and doxycycline
and 16 weeks for cefoperazone and piperacillin.
FIG. 3. Immunoblot analysis of P-gp expression in cell lysates from
MCF-7 sublines. Cell extracts (50 g of protein) were electrophoresed,
transferred, and immunoblotted with monoclonal (C219) anti-human
P-gp antibody. A monoclonal antibody recognizing actin (45 kDa) was
used to normalize protein load. The analysis was repeated twice with
protein extracts from separate cell lysates. Final concentrations of
drugs were as follows: doxorubicin, 2 g/ml (3 M); doxycycline, 100
g/ml (208 M); cefoperazone, 2 mg/ml (3 mM); and piperacillin, 8
mg/ml (14 mM). Solubility problems prevented further increases in
cefoperazone and piperacillin concentrations. The duration of drug
exposure was approximately 12 weeks for doxorubicin and doxycycline
and 16 weeks for cefoperazone and piperacillin. Numbers to the left of
the top panel are molecular masses in kilodaltons.
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greatest chance of survival in the presence of cytotoxic agents,
provided that the cytotoxic drug is a substrate for P-gp. Based
on this rationale, one would predict that an experimental drug
must be both cytotoxic and a substrate for P-gp in order to
generate a subline of P-gp-overexpressing, MDR cells. As
shown in Fig. 5A, doxorubicin and doxycycline were cytotoxic
to P-gp-negative MCF-7 cells whereas no cytotoxicity was ob-
served after a 24-h treatment with cefoperazone or piperacil-
lin, drugs that failed to generate P-gp overexpression. Exper-
iments were then performed to determine if MCF-7/Adr cells
were protected against doxycycline-induced cytotoxicity (Fig.
5B). After incubation with doxycycline for 24 h, MCF-7/Adr
cells were more resistant to doxycycline-induced cytotoxicity
than were P-gp-negative MCF-7 cells. When P-gp function was
inhibited by addition of verapamil, MCF-7/Adr cells became
susceptible to drug-induced cytotoxicity. Interestingly, it ap-
pears that addition of verapamil to MCF-7/Adr cells increased
the cytotoxicity of all drugs, not just doxorubicin and doxycy-
cline (Fig. 5B). Since verapamil had no effect on doxycycline-
induced cytotoxicity in P-gp-negative MCF-7 cells, it is reason-
able to assume that P-gp-mediated drug efflux is at least
partially responsible for protection of MCF-7/Adr cells. How-
ever, it is likely that induction of P-gp expression requires a
combination of several factors, one of which may be exposure
to a cytotoxic drug that is a P-gp substrate.
DISCUSSION
In the present study, the effects of antimicrobial agents on
P-gp expression in MCF-7 breast carcinoma cells were inves-
tigated. Results indicate that doxycycline, but not cefopera-
zone or piperacillin, increases P-gp expression and confers the
MDR phenotype, namely, reduced intracellular accumulation
of doxorubicin and reversal of this response by the chemosen-
sitizing agent verapamil. In all aspects studied, MCF-7/doxy
cells appear identical to the well-characterized P-gp-overex-
pressing positive-control cell line, MCF-7/Adr. This is the first
report of a clinically relevant, nonanticancer drug generating
P-gp expression in a cancer cell line. Doxycycline is used for
treating a variety of infectious diseases in cancer patients (29,
33, 44). It has also been used previously for chemical pleurode-
sis in patients with malignant pleural effusions (15, 39) and is
currently being investigated as an antiangiogenic agent for the
FIG. 4. Digital images of doxorubicin accumulation in MCF-7/Adr (right) and MCF-7/doxy (left) cells. Images at the top represent cells treated
with 5 M doxorubicin for 18 h. Bottom panel represents cells treated with doxorubicin and 10 M verapamil. Because of the inherent fluorescence
of the doxorubicin molecule, fluorescence intensity (scale at far right) corresponds to relative doxorubicin concentrations.
TABLE 1. Intracellular concentrations of doxorubicin in parental
MCF-7 cells and drug-selected sublines as determined by
laser cytometry
Drug
Concn (M) of doxorubicin in cell linea:
MCF-7 MCF-7/Adr MCF-7/doxy
Doxorubicin 700 (7.7) 329‡ (5.8) 221§ (5.9)
Doxorubicin  verapamil 770† (5.6) 770† (5.1) 756† (7.1)
a Values are expressed as means (standard errors). Values identified with
different symbols are significantly different (P  0.05).
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treatment of cancer (19, 23). Administration of doxycycline to
cancer patients could result in clinical chemotherapeutic fail-
ure as a consequence of generating P-gp-expressing, MDR
tumor cell clones.
It is interesting that the most common form of tetracycline
resistance among bacteria is via a plasmid-derived, inducible
membrane protein that promotes energy-dependent efflux of
the tetracyclines (28). Human MDR1 cDNA was recently
cloned into a prokaryotic expression vector, resulting in ex-
pression of a full-length, immunoreactive, apparently func-
tional P-gp molecule in the membrane fraction of transfected
Escherichia coli (17). These cells displayed increased resistance
to the P-gp substrates puromycin, tetraphenylphosphonium
ion, and tetraphenylarsonium ion. Moreover, cells expressing
P-gp demonstrated reduced intracellular accumulation of tet-
racycline compared to that of cells that did not express P-gp.
These results are in agreement with our findings that suggest
that doxycycline (a semisynthetic derivative of tetracycline) is a
substrate for P-gp.
The conditions under which MDR is acquired during che-
motherapy remain poorly understood. Both induction of P-gp
expression in previously negative cells and selection of che-
moresistant, P-gp-positive cells may be involved in the devel-
opment of an MDR phenotype in a clinical setting. In cell
culture systems, overexpression of P-gp may be a result of
transcriptional upregulation (10, 32), gene amplification (12),
or RNA stabilization (18). For resistant cell lines generated in
this study, it is doubtful that selection alone was responsible for
increased MDR1 mRNA and P-gp expression. Cells utilized in
this study were expanded from a single cell clone that did not
express MDR1 mRNA or P-gp; therefore, selection of a pre-
viously drug-resistant population did not occur.
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